Vistagen Therapeutics Q1 2024 Earnings Report $2.50 +0.25 (+11.11%) (As of 12/20/2024 05:40 PM ET) Earnings HistoryForecast Vistagen Therapeutics EPS ResultsActual EPS-$0.94Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AVistagen Therapeutics Revenue ResultsActual Revenue$0.18 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVistagen Therapeutics Announcement DetailsQuarterQ1 2024Date8/10/2023TimeN/AConference Call ResourcesPress ReleaseVTGN Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Vistagen Therapeutics Earnings HeadlinesStifel Nicolaus Sticks to Their Buy Rating for VistaGen Therapeutics (VTGN)November 22, 2024 | markets.businessinsider.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call TranscriptNovember 11, 2024 | insidermonkey.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 21, 2024 | Brownstone Research (Ad)Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comVistaGen Therapeutics’ Promising Clinical Progress and Strong Financial Position Justify Buy RatingNovember 9, 2024 | markets.businessinsider.comVistagen Therapeutics Reports Increased R&D ExpensesNovember 8, 2024 | markets.businessinsider.comSee More Vistagen Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vistagen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vistagen Therapeutics and other key companies, straight to your email. Email Address About Vistagen TherapeuticsVistagen Therapeutics (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.View Vistagen Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
